Background and Purpose-The Secondary Prevention of Small Subcortical Stroke trial (SPS3) recruited participants meeting clinical and radiological criteria for symptomatic lacunes. Individuals randomized to dual antiplatelet therapy with clopidogrel and aspirin had an unanticipated increase in all-cause mortality compared with those assigned to aspirin. We investigated the factors associated with mortality in this well-characterized population. Methods-We identified independent predictors of mortality among baseline demographic and clinical factors by Cox regression analysis in participants of the SPS3 trial. Separately, we examined the effect on mortality of nonfatal bleeding during the trial. Results-During a mean follow-up of 3.6 years, the mortality rate was 1.78% per year for the 3020 participants (mean age, 63 years). Significant independent predictors of mortality at study entry were age, diabetes mellitus, history of hypertension, systolic blood pressure (hazard ratio [HR], 1.3 per 20 mm Hg increase), serum hemoglobin <13 g/dL (HR, 1.6), renal function (HR, 1.3 per estimated glomerular filtration rate decrease of 20 mL/min), and body mass index (HR, 1.8 per 10 kg/m 2 decrease). Participants with ischemic heart disease (P=0.01 for interaction) and normotensive/prehypertensive participants (P=0.03 for interaction) were at increased risk if assigned to dual antiplatelet therapy. Nonfatal major hemorrhage increased mortality in both treatment arms (HR, 4.5; 95% confidence interval, 3.1-6.6; P<0.001). Conclusions-Unexpected interactions between assigned antiplatelet therapy and each of ischemic heart disease and normal/prehypertensive status accounted for increased mortality among patients with recent lacunar stroke given dual antiplatelet therapy. Despite extensive exploratory analyses, the mechanisms underlying these interactions are uncertain. Clinical Trial Registration-URL: http://www.SPS3ClinicalTrials.gov. Unique identifier: NCT00059306.
L acunar infarcts, or small subcortical strokes, represent 25% of all ischemic strokes, are associated with cognitive and functional impairment, and are frequently discovered on brain imaging without a prior clinical presentation (ie, covert infarcts). [1] [2] [3] [4] Hypertension is associated, and the pathology is often in the small penetrating arteries of the brain. 5, 6 Little is known about the predictors of mortality in those with lacunar infarcts. The Secondary Prevention of Small Subcortical Strokes (SPS3) trial tested 2 levels of blood pressure control and dual antiplatelet therapy (aspirin plus clopidogrel) versus monotherapy (aspirin plus placebo) in patients with a recent symptomatic lacunar stroke verified by MRI. All-cause mortality was increased in those assigned dual antiplatelet therapy with higher mortality for vascular and nonvascular causes of death. 7 A meta-analysis of trials of dual antiplatelet therapy versus aspirin monotherapy did not show a similar association, suggesting that the results of SPS3 were unique. 8 Although fatal hemorrhage was more common in the dual antiplatelet arm (9 versus 4 cases), the number of fatal bleeds was insufficient to explain the difference in mortality. 7 We sought to determine the predictors of mortality in this population and hypothesized that the increased mortality might be the result of higher rates of nonfatal hemorrhage in the dual antiplatelet therapy group.
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were without surgically amenable ipsilateral carotid artery disease (hemispheral infarcts) or major-risk cardioembolic sources (all infarcts) were eligible and randomized simultaneously in a 2×2 factorial design, either to single or dual antiplatelet therapy (aspirin plus placebo versus aspirin plus clopidogrel; double-blind) and to 1 of 2 target levels of systolic blood pressure control (130-149 versus <130 mm Hg; open-label). Participants with a clinical lacunar syndrome were required to meet MRI criteria. 7 MRI eligibility was determined by local investigators, with images submitted for central interpretation by a neuroradiologist. Disabling strokes (modified Rankin Scale score ≥4) were excluded.
Prior lacunar stroke or transient ischaemic attack was identified only when a clinical episode antecedent to the qualifying event consistent with a classic subcortical ischemic stroke syndrome was documented and was not based solely on neuroimaging findings. Severity of hypertension was determined from the systolic blood pressure at entry adjusted by the number of antihypertensive medications. Specifically, the average of 2 screening systolic blood pressure measurements (3 measurements each visit) taken at least 1 week apart was adjusted by adding 5 mm Hg for each antihypertensive medication (up to a maximum of 4) at the time of measurement. Normotensive was defined as <120 mm Hg, prehypertensive as 120 to <140 mm Hg, stage I hypertension as 140 to <160 mm Hg, and stage II hypertension as ≥160 mm Hg. For these analyses, we combined normotensives and prehypertensives into 1 group. Participants with a history of myocardial infarction, angina pectoris, as well as those who had undergone coronary artery bypass, coronary angioplasty, or stenting were identified as having ischemic heart disease. Estimated glomerular filtration rate was computed using the Chronic Kidney Disease Epidemiology Collaboration equation. 12 Hemorrhage during the trial was defined as major if serious or lifethreatening if it met any of the following criteria: urgent hospitalization or emergency medical treatment, transfusion of red blood cells (excluding that associated with coronary artery bypass graft, openheart, or elective surgery), residual functional sequelae, or surgical therapy for bleeding.
The antiplatelet arm of SPS3 was stopped on recommendation of the data and safety monitoring committee after a planned interim analysis when two third of the primary events had occurred because of futility and evidence of harm (increased mortality in patients assigned dual antiplatelet therapy). For this analysis, we considered deaths that occurred until the time that the antiplatelet trial was terminated; 16 additional deaths that occurred during continuation of the blood pressure trial were not considered. One additional death was discovered after reporting of the main results. 7 The cause of death was adjudicated by a central events committee blinded to treatment assignment and classified as vascular cerebral, vascular noncerebral, probable vascular, nonvascular, or uncertain. Disagreements were resolved by consensus.
All analyses followed the intention-to-treat principle. Patient demographic and clinical characteristics were summarized by treatment group using proportions for categorical variable and means and SDs for continuous variable. The distributions of continuous variables were assessed for normality and found to be approximately normally distributed with the exception of the body mass index. Body mass index was further classified as: <18.5 (underweight), 18.5 to 24.9 (normal), 25 to 29.9 (overweight), and ≥30 kg/m 2 (obese). Crude (univariate) hazard ratios (HRs) and the 95% confidence intervals (CIs) for each of the patient demographic and clinical characteristics were computed separately by assigned antiplatelet treatment groups. To determine independent predictors of mortality, variables univariately associated with increased risk of death (P<0.05) in 1 or both treatment groups along with assigned antiplatelet treatment group were then considered in a multivariable Cox proportional hazards regression model. Forward-stepwise regression was used to identify independent predictors, and interaction terms between assigned antiplatelet treatment and patient characteristic were investigated if the main effect term for the patient characteristic was statistically significant. HR estimates and 95% CIs were reported for variables independently predictive of mortality. Mortality and other event rates were computed by dividing the total number of deaths (or other event) by the total number of patient-years of exposure for each assigned treatment group. Confidence intervals for event rates were computed assuming a Poisson distribution. The time to major hemorrhage was calculated as the time to the first one in the case of multiple hemorrhages and analyzed as a time-dependent variable. Exposure for patients without a major hemorrhage was censored at the time of termination of study participation or at death. Statistical significance was accepted at the 0.05 level, and all tests were 2-sided. Analyses were done using SPSS 20.0 (Armonk, NY).
Results
Among the 3020 participants with recent lacunar stroke, the mean age was 63 years and the frequencies of hypertension, diabetes mellitus, and ischemic heart disease were 80%, 37%, and 10%, respectively. During 10 758 years of follow-up for the antiplatelet trial (mean, 3.6 years; range, 0-8.2 years), there were 191 deaths (annualized rate, 1.78%). All-cause mortality was increased in the group assigned dual antiplatelet therapy compared with those assigned aspirin monotherapy (113 versus 78 deaths; HR, 1.5; 95% CI, 1.1-2.0). Mortality did not vary by assigned blood pressure target at the time the antiplatelet trial was terminated. Major bleeding was increased in the dual antiplatelet therapy arm but was not affected by blood pressure target assignment (Table 1 ).
Factors at Study Entry Associated With Mortality
Patient demographic and clinical characteristics examined for an association with mortality are shown in Table 2 . Participants in either assigned antiplatelet group who were older (an average of 7 years), had lower body mass index, were diabetic, a history of hypertension, or reduced renal function had increased risk of death. Those assigned to dual antiplatelet therapy with a history of ischemic heart disease, lower diastolic blood pressure, less severe hypertension, aspirin use at the time of the qualifying event, and lower hemoglobin were also at higher risk.
By multivariable analysis, independent predictors at study entry of death were increasing age, lower body mass index, history of hypertension, higher systolic blood pressure, diabetes mellitus, hemoglobin <13 g/dL, and lower estimated The 3020 participants were randomized in a 2×2 factorial design to aspirin and higher SBP (systolic blood pressure) target, n=755; aspirin and lower target, n=748; clopidogrel plus aspirin and higher target, n=764; and clopidogrel plus aspirin and lower target, n=753.
*Hazard ratio (HR) 1.5 for clopidogrel plus aspirin vs aspirin monotherapy; 95% confidence interval (CI), 1.1-2.0; P=0.006. †HR 1.1 for lower vs higher BP target; 95% CI, 0.86-1.5; P=0.4.
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http://stroke.ahajournals.org/ Downloaded from glomerular filtration rate with no statistically significant interaction between any of these factors and antiplatelet therapy assignment (Table 3) . However, patients assigned to dual antiplatelet therapy with ischemic heart disease (P=0.01 for interaction) and normotensive/prehypertensive patients (P=0.03 for interaction) were at increased risk of death (Table 3 ; Figure) . For the 71% of participants who were stage I or II hypertensive but without ischemic heart disease, the mortality rates were equal between antiplatelet arms. There was no significant imbalance in these factors between the antiplatelet assignments. Estimates of HRs were not appreciably changed by the exclusion of history of hypertension as a variable. 
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Nonfatal Hemorrhage and Mortality
We hypothesized that nonfatal major hemorrhage would be associated with death and that assignment to dual antiplatelet therapy would be associated with a higher rate of nonfatal major hemorrhage. A major hemorrhage during the study period was independently predictive of mortality (HR, 4.5; 95% CI, 3.1-6.6; P<0.001) when added to the model with patient characteristics at study entry (Table 3) . No important effect on HR estimates in that model was observed, and the increased risk of death with major hemorrhage was not increased for patients assigned dual antiplatelet therapy (P=0.7 for interaction). Of the 161 patients who had a major hemorrhage, the first was fatal for 13 patients (9 assigned dual antiplatelet therapy). Those assigned dual versus monotherapy had a higher rate of nonfatal major hemorrhage (n=96, 1.9%/patient-year versus n=52, 1.0%/patient-year; P<0.001).
Regardless of assigned antiplatelet treatment, the mortality rate was higher for patients with a nonfatal major hemorrhage compared with those with no major hemorrhage (dual: 4.2% versus 1.8%/patient-year; P=0.002; mono: 3.1% versus 1.3%/ patient-year; P=0.03; Table 4 ).
Discussion
The observation of increased mortality in individuals with lacunar stroke assigned dual antiplatelet therapy was unexpected. We undertook data-driven analyses to assess the differential mortality observed with dual antiplatelet therapy in SPS3. Participants with a history of ischemic heart disease had a significantly higher mortality rate when assigned to dual antiplatelet therapy compared with those assigned to aspirin, despite evidence that dual antiplatelet therapy prevents myocardial infarction better than aspirin in populations with vascular disease. 8 Those assigned dual antiplatelet therapy were at increased risk of death if they were normotensive/prehypertensive and had no history of ischemic heart disease. Although this may be a chance association, the definition of lacunar stroke in SPS3 was rigorous, requiring MRI confirmation, and may have selected for a unique mixture of vascular pathology with an unexpected response to the trial interventions.
Bleeding was associated with mortality in the SPS3 cohort. There were more fatal and nonfatal major bleeds in the dual treatment arm, and major nonfatal bleeds correlated with mortality. The association between nonfatal major bleeding and mortality is plausible because it may lead to physician discontinuation of medications or nonadherence by patients. 13 The proportion of patients with nonfatal major bleeding in SPS3 was 6.3% in the dual antiplatelet group and 3.5% in the monotherapy group during a mean follow-up of 43 months. These rates are similar to those observed in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial that compared dual therapy to aspirin in individuals at high vascular risk. 14 We lacked detailed data on exposure time for nonassigned treatments in participants who withdrew permanently from assigned antiplatelet therapy and cannot exclude antiplatelet nonadherence as an explanation of the excess mortality associated with nonfatal major hemorrhage. Nonadherence is unlikely to be the complete explanation for the difference in mortality because the increase in vascular mortality in those assigned dual antiplatelet therapy was insufficient to explain the mortality difference between antiplatelet arms (Table 5) . This likely reflects an overlap of factors that affect vascular and nonvascular mortality. In addition, the assignment of cause of death by record review is inherently imprecise and a limitation of our analysis.
In general populations, obese individuals experience significantly higher all-cause mortality when compared with normal-weight individuals, whereas those overweight have significantly lower mortality, suggesting a J-shaped relationship. 15 In SPS3 we found a linear, inverse relationship between body mass index and mortality with no interaction with treatment assignment. This may be partially explained by confounding because of smoking or pre-existing disease. 16 Although we cannot exclude pre-existing disease, adjustment for smoking did not weaken the association between lower body mass index and mortality. A similar association has been observed in recent observational studies of stroke cohorts. 17, 18 The mechanism for this observation, termed the obesity paradox, remains unexplained. [19] [20] [21] [22] Mortality risk after lacunar infarct was 8% in the first year in a recent systematic review (n=544). 23 Although this is substantially higher than we observed, there are several limitations in the observational cohorts that include relatively small numbers, poor and variable definition of lacunar stroke, variable follow-up, and a mean age of 71 years (SPS3 mean age, 63). Our analyses have been done in a population that met trial inclusion criteria with aggressive management of blood pressure and high prevalence of statin therapy, which likely contributed to lower mortality than found in the systematic review. Independent predictors of mortality in patients with MRI-defined lacunar infarcts have not been previously defined. We identified 7 independent predictors at study entry of mortality: age, lower body mass index, hemoglobin <13 g/dL, lower estimated glomerular filtration rate , history of hypertension, increased systolic blood pressure, and diabetes mellitus. Nonfatal major hemorrhage during the course of the trial was also associated with increased mortality.
A systematic review and meta-analysis of the effect of the addition of clopidrogel to aspirin on mortality identified SPS3 results as an outlier and noted that overall adding clopidogrel to aspirin does not increase mortality. 8 An interaction between dual therapy and mortality has been observed in the asymptomatic and primary prevention subsets of the CHARISMA population with increased mortality risk in those assigned dual therapy. 24 The SPS3 population behaves similar to the low-risk population in CHARISMA, suggesting that individuals with lacunar infarct form a distinct subset of those with established vascular disease and have increased risk of mortality on dual antiplatelet therapy.
Our study has several limitations. The population included in the study was relatively healthy stroke survivors recruited a median of 62 days after the qualifying stroke. Classification of death as vascular or nonvascular was dependent on the narrative supplied by the trial sites. We did not correct for multiple comparisons, and the results must be interpreted with caution.
In conclusion, participants in SPS3, although experiencing a lower mortality rate than previously reported lacunar stroke populations, had higher mortality when assigned dual antiplatelet therapy, which was not explained by fatal hemorrhage. It is unlikely to be explained by nonadherence to antiplatelet therapy because vascular mortality did not differ significantly between groups. Unexpected interactions were observed between dual antiplatelet therapy and absence of hypertension and history of ischemic heart disease with increased mortality in both subgroups. This observation, if confirmed in other data sets, has implications for the design of trials testing combination antiplatelet therapy and its broader use in stroke populations.
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